1. Clinical & Scientific Overview
Tiotropium Bromide (TIP-MED-000169, Reference Code [9.5]) is classified under
Respiratory, Asthma, COPD & Allergy Medicines (Ch 09) as a Long-Acting Muscarinic Antagonist (LAMA; 24-Hour M3-Selective Anticholinergic Bronchodilator).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 09 [9.5], p. 116): Tiova (Cipla—Inhaler, Rotacaps), Spiriva HandiHaler / Respimat (Boehringer Ingelheim), Aerotrop; In FDC with Formoterol: Duova (Cipla), Tiomate; In Triple FDC (Tiotropium + Formoterol + Ciclesonide/Budesonide): Triohale, Airtec-FF — Strengths & Dosage Forms: pMDI Inhaler (Tiova): 9 mcg/puff (2 puffs once daily = 18 mcg); Rotacaps (DPI): 18 mcg/capsule (1 capsule once daily); Respimat Soft Mist: 2.5 mcg/puff
pMDI Inhaler (Tiova): 9 mcg/puff (2 puffs once daily = 18 mcg); Rotacaps (DPI): 18 mcg/capsule (1 capsule once daily); Respimat Soft Mist: 2.5 mcg/puff
3. Mechanism of Action & Pharmacodynamics
Long-Acting Muscarinic Antagonist (LAMA; 24-Hour M3-Selective Anticholinergic Bronchodilator) acting on target receptor/enzyme pathways in Respiratory, Asthma, COPD & Allergy Medicines (Ch 09): clinical efficacy is mediated via Long-Acting Muscarinic Antagonist (LAMA; 24-Hour M3-Selective Anticholinergic Bronchodilator) for Cornerstone first-line 24-hour maintenance bronchodilator for COPD (reduces hyperinflation, dyspnoea, and COPD exacerbations); add-on maintenance bronchodilator in severe persistent asthma uncontrolled on ICS + LABA..
4. Therapeutic Indications & Evidence-Supported Uses
- Cornerstone first-line 24-hour maintenance bronchodilator for COPD (reduces hyperinflation, dyspnoea, and COPD exacerbations)
- add-on maintenance bronchodilator in severe persistent asthma uncontrolled on ICS + LABA
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Strictly ONCE DAILY (every 24 hours): Rotacap DPI: Inhale the powder of 1 capsule (18 mcg) once daily via Rotahaler/HandiHaler. pMDI (9 mcg): Inhale 2 puffs once daily. Follow physician prescription.
Administration & Meal Timing: Inhaled: Independent of food. | Once daily at the same clock hour every morning.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Excreted primarily unchanged in urine (~74% of absorbed dose)! In moderate-to-severe renal impairment (CrCl ≤50 mL/min), plasma concentrations double—monitor closely for anticholinergic side effects (urinary retention, tachycardia, dry mouth). Hepatic: No adjustment required.
Renal: Excreted primarily unchanged in urine (~74% of absorbed dose)! In moderate-to-severe renal impairment (CrCl ≤50 mL/min), plasma concentrations double—monitor closely for anticholinergic side effects (urinary retention, tachycardia, dry mouth). Hepatic: No adjustment required.
Renal: Excreted primarily unchanged in urine (~74% of absorbed dose)! In moderate-to-severe renal impairment (CrCl ≤50 mL/min), plasma concentrations double—monitor closely for anticholinergic side effects (urinary retention, tachycardia, dry mouth). Hepatic: No adjustment required.
7. Contraindications, Precautions & High-Risk Warnings
- NOT for acute rescue of sudden bronchospasm! Use with caution in patients with Narrow-Angle Glaucoma (if powder or mist accidentally enters the eyes, it causes pupillary dilation [mydriasis] and precipitates acute angle-closure glaucoma with severe eye pain and blurred vision!), Benign Prostatic Hyperplasia (BPH) or bladder-neck obstruction (can worsen urinary hesitancy or precipitate acute urinary retention in elderly men!), and moderate-to-severe renal impairment.
Key Clinical Precautions: Renal: Excreted primarily unchanged in urine (~74% of absorbed dose)! In moderate-to-severe renal impairment (CrCl ≤50 mL/min), plasma concentrations double—monitor closely for anticholinergic side effects (urinary retention, tachycardia, dry mouth). Hepatic: No adjustment required.
8. Adverse Effects Profile
- Dry mouth (xerostomia, 10–16%), mild constipation, pharyngitis, sinusitis, cough, bitter taste.
- Acute Angle-Closure Glaucoma (if sprayed/blown into eyes: eye pain, red eye, coloured halos around lights, blurred vision—ophthalmic emergency!), Acute Urinary Retention in men with BPH, supraventricular tachycardia / atrial fibrillation (rare), paradoxical bronchospasm, angioedema.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Do NOT combine with another antimuscarinic bronchodilator (such as Ipratropium [Duolin/Iprazest], Glycopyrronium, or Umeclidinium)! (Frequently happens when a COPD patient on daily Tiova is also prescribed regular nebulised Duolin at home—causing duplicate muscarinic blockade, severe dry mouth, constipation, and urinary retention!)
- Additive systemic anticholinergic burden with Solifenacin/Tolterodine, Amitriptyline, and first-generation antihistamines
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: 1. Eye Protection Rule: When inhaling Tiova pMDI or opening Tiova Rotacaps, close your eyes or ensure the mist/powder never blows into your eyes, and wash hands after handling capsules—getting tiotropium in the eye dilates the pupil and can trigger acute glaucoma. 2. For Rotacaps: Inhale twice from the same pierced capsule to ensure all powder is emptied, and never swallow the capsule. 3. Take sips of water for dry mouth (mouth rinsing for thrush is only mandatory if using a steroid combination like Triohale).
- Meal & Clock Timing Instruction: Inhaled: Independent of food. (Once daily at the same clock hour every morning.)
- Missed Dose Protocol: Inhale as soon as remembered on the same day; never inhale more than one 18 mcg dose in 24 hours.
- Geriatric Dispensing Pearl: Before dispensing Tiova to an elderly male CGHS patient, always ask if he has prostate enlargement (BPH / taking Tamsulosin) or glaucoma, and advise him to report any difficulty passing urine immediately. Screen out duplicate chronic home nebulisation with Ipratropium (Duolin) alongside daily Tiova.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: pMDI Inhaler (Tiova): 9 mcg/puff (2 puffs once daily = 18 mcg); Rotacaps (DPI): 18 mcg/capsule (1 capsule once daily); Respimat Soft Mist: 2.5 mcg/puff
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 09 [9.5] (p. 116)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [9.15] Roflumilast — Selective Phosphodiesterase-4 (PDE-4) Anti-Inflammatory Inhibitor
- [9.16] N-Acetylcysteine (Oral/Inhaled Mucolytic) & Ambroxol / Bromhexine — Sulfhydryl Disulfide-Bond Mucolytic + Glutathione Precursor & Muc
- [9.17] Dextromethorphan Hydrobromide & Levodropropizine — Central Medullary Sigma-1/NMDA Cough Suppressant & Peripheral Sen
- [9.18] Fexofenadine Hydrochloride & Bilastine — Non-Sedating Second-Generation P-gp Substrate Histamine H1-Recept
